GS
NTLA icon

GWN Securities’s Intellia Therapeutics NTLA Stock Holding History

GWN Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Buy
31,484
+10,641
+51% +$136K 0.08% 286
2025
Q4 		$187K Buy
20,843
+8,219
+65% +$113K 0.04% 430
2025
Q3 		$218K Buy
+12,624
New +$155K 0.05% 343

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GWN Securities's NTLA Position: Q1 2026 in Review

GWN Securities increased its Intellia Therapeutics (NTLA) stake by 51% in Q1 2026, buying an estimated $136K and bringing the position to 31,484 shares worth $404K. The position accounts for 0.08% of the portfolio, ranked #286.

GWN Securities first reported a position in NTLA in Q3 2025 and has held it in 3 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • GWN Securities held 31,484 shares of Intellia Therapeutics worth $404K as of Q1 2026.
  • GWN Securities bought 10,641 Intellia Therapeutics shares in Q1 2026, an estimated $136K.
  • Intellia Therapeutics made up 0.08% of GWN Securities's portfolio in Q1 2026, its #286 holding.
  • GWN Securities first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on GWN Securities's 13F filing for Q1 2026, filed 15 May 2026.